Exploring an Expanding AML Therapeutic Armamentarium: Expert Guidance to Optimize Outcomes

Exploring an Expanding AML Therapeutic Armamentarium: Expert Guidance to Optimize Outcomes

Thursday, June 17, 2021
Webinar -- 6:30 PM ET
https://www.clinicaloptions.com/ChicagoNCCNAML2021Join1

Agenda

  • Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
  • Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
  • Immunotherapeutic Principles and a Potential Paradigm Shift in the Management of AML
  • New and Novel Advances in AML Therapeutics—Future Approaches to BMT and Targeted Therapies

Faculty

Program Director
Daniel A. Pollyea, MD, MS

Associate Professor of Medicine
Clinical Director of Leukemia Services
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Faculty
Amir Fathi, MD

Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Faculty
Eunice Wang, MD

Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with AML.

Target Audience
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with AML.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, assessment of measurable residual disease, and therapeutic decisions
  • Plan evidence-based therapeutic strategies for older unfit patients, those with preexisting comorbidities, and/or those with secondary AML using novel targeted agents or formulations and refinements of conventional chemotherapy
  • Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations or positive for CD33
  • Assess the available evidence to optimally integrate immunotherapeutic agents, including monoclonal antibody–based therapy, immune checkpoint inhibitors, vaccines, and adoptive cell–based therapy
  • Address patient-specific challenges surrounding pre- and posttransplant processes and novel agents to mitigate risk
  • Manage treatment-related toxicities associated with novel therapeutics

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
NCCN designates this educational activity for a maximum of 1.5 contact hours.

Pharmacist Continuing Education

NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-21-040-L01-P

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.

Physician Assistant Continuing Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. Full disclosure of faculty relationships will be made prior to the activity. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.